Novel 5-azaindole factor VIIa inhibitors
We have developed a series of potent and selective factor VIIa inhibitors based on the 2-[5-(5-carbamimidoyl-1 H-benzoimidazol-2-yl)-6-hydroxy-biphenyl-3-yl]- succinic acid scaffold. These biaryl amidine-containing compounds suffer from low oral bioavailability. In an attempt to apply the knowledge...
Saved in:
Published in | Bioorganic & medicinal chemistry letters Vol. 16; no. 12; pp. 3197 - 3200 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ltd
15.06.2006
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We have developed a series of potent and selective factor VIIa inhibitors based on the 2-[5-(5-carbamimidoyl-1
H-benzoimidazol-2-yl)-6-hydroxy-biphenyl-3-yl]- succinic acid scaffold. These biaryl amidine-containing compounds suffer from low oral bioavailability. In an attempt to apply the knowledge we have gained from our amidine fVIIa inhibitor parenteral program to an oral program, we began with our 5-amidinobenzimidazole scaffold and replaced the amidine with a less basic 5-azaindole (1
H-pyrrolo[3,2-
c]pyridine,
2). The discovery and development of 5-azaindole factor VIIa inhibitors will be described.
The discovery and development of 5-azaindole factor VIIa inhibitors will be described. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0960-894X 1464-3405 |
DOI: | 10.1016/j.bmcl.2006.03.049 |